Objective To sort out the cases of adverse drug reactions（ADRs）in gynecological cancer patients in West China Second University Hospital of sichuan University using platinum-based anti-tumor drugs in our hospital over the past three years，and to analyze the characteristics of new ADRs，so as to promote clinical safety of drug use.Methods Platinum-based ADR reports submit⁃ ted to National Center for ADR Monitoring system by West China Second University Hospital of Sichuan University from October 1，2019 to September 30，2022 were retrospectively collected.General information of patients，drug types used，primary diseases and other information were summarized，and the incidence and proportion of related ADRs were calculated.Results In the past three years，134 cases of platinum-based anti-tumor drug ADRs were reported in our hospital，among which 125 cases were gynecological cancer pa⁃ tients with original disease，51 cases（40.80%）were reported as new ADRs，and ovarian cancer patients were the majority（58.82%）.The number of ADR and new ADR cases in 51 ~ 60 years old group was the largest，accounting for more than 40%.The proportion of new ADRs of different platinum-based anti-tumor drugs was between 38% and 50%，and most of the correlations were very likely （94.12%）.The occurrence time of new ADR of these drugs was concentrated within 24 h（88.24%），and the main organ or system in⁃ volved was allergy（systemic reaction）（72.55%），followed by nervous system（35.29%）.Conclusions Gynecological cancer patients who use platinum-based anti-tumor drugs are at high risk of new ADRs，which occur rapidly and are concentrated in the 51 ~ 60 age group.The different platinum-based drugs had certain characteristics in terms of the systems they affect.Clinical pharmacists and medical staff should be attentive to recognizing，actively treating，timely reporting，and summarizing ADRs to provide guidance for im⁃ proving clinical drug safety in the future.